• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

News

Article

January 17, 2025

FDA Targets Nicotine to Reduce Lung Cancer and Other Tobacco-Related Diseases

Author(s):

Kennedy Ferruggia, Assistant Editor

Key Takeaways

  • The FDA's proposed rule aims to reduce nicotine levels in combusted tobacco products, making them minimally or non-addictive.
  • The nicotine cap is set at 0.7 mg per gram of tobacco, significantly lower than current levels.
  • The rule targets cigarettes, most cigars, and pipe tobacco, excluding e-cigarettes and smokeless tobacco.
  • The initiative could prevent millions of youths from starting smoking and help current smokers quit, potentially averting 1.8 million tobacco-related deaths.
SHOW MORE

The FDA proposes to cap the nicotine level at 0.7 mg per gram of tobacco in cigarettes and certain other combusted tobacco products.

On Wednesday, the FDA announced a proposed a rule that would significantly reduce nicotine levels in cigarettes and other combusted tobacco products, making them minimally or non-addictive, a groundbreaking move that could drastically reduce smoking-related illnesses and deaths in the US.1

Close up male hand holding a cigarette - Image credit: Nopphon | stock.adobe.com

Image credit: Nopphon | stock.adobe.com

Nicotine, the addictive substance in tobacco products, particularly in combusted forms like cigarettes, exposes users to harmful chemicals that cause disease and death. The proposed rule aims to reduce nicotine levels in these products as research indicates that lower nicotine content does not lead to increased smoking.1

“Today’s proposal envisions a future where it would be less likely for young people to use cigarettes and more individuals who currently smoke could quit or switch to less harmful products,” Robert M. Califf, MD, commissioner of the FDA, said in a news release.1

Rather than banning cigarettes or tobacco products, the FDA is proposing to cap the nicotine level at 0.7 mg per gram of tobacco in cigarettes and certain other combusted tobacco products.1 This is a significant decrease as the current average concentration of nicotine per cigarette is around 10 mg to 12 mg. However, 1 mg to 2 mg is absorbed by the smoker when inhaled.2

The FDA reported that the proposed rule would apply to cigarettes, cigarette tobacco, roll-your-own tobacco, most cigars (including little cigars, cigarillos, and most large cigars), and pipe tobacco. However, the proposed rule will not apply to e-cigarettes, nicotine pouches, noncombusted cigarettes (such as heated tobacco products that meet the definition of a cigarette), waterpipe tobacco (hookah), smokeless tobacco products, or premium cigars.1

“This action, if finalized, could save many lives and dramatically reduce the burden of severe illness and disability, while also saving huge amounts of money. I hope we can all agree that significantly reducing the leading cause of preventable death and disease in the US is an admirable goal we should all work toward,” Califf said in a news release.1

Cigarettes and other combusted tobacco products are the most harmful forms of tobacco, with cigarette smoking being the leading preventable cause of death and a major contributor to chronic diseases in the US, resulting in an estimated half a million deaths and over $600 billion in annual costs.1

According to the CDC, cigarette smoking is also the leading risk factor for lung cancer and is linked to about 80% to 90% of lung cancer deaths. Additionally, individuals that smoke cigarettes are 15 to 30 times more likely to develop lung cancer or die from the disease compared to individuals who do not smoke. Occasional smoking is also reported to increase lung cancer risk; however, individuals that quit smoking have a lower risk than if they continued to smoke. Despite eliminating cigarette use, the risk is still higher among individuals that quit compared to individuals who never smoked. The use of other tobacco products such as cigars and pipes also increase an individual’s risk of developing lung cancer.3

The FDA noted that the proposed rule is projected to have immense public health benefits, preventing approximately 48 million US youths from starting to smoke by the year 2100. Additionally, it will aid 12.9 million current smokers to quit, with a predicted estimate of 19.5 million individuals within 5 years of the rule being finalized which could avert 1.8 million tobacco-related deaths. The decrease in fatal smoking outcomes could generate over $1.1 trillion annually over the next 4 decades.1

“Today, we’re taking a critical step in the rulemaking process by providing the public with a proposal they can review and engage on,” Brian King, PhD, MPH, director of the FDA’s Center for Tobacco Products, said in the news release. “This proposal allows for the start of an important conversation about how we meaningfully tackle one of the deadliest consumer products in history and profoundly change the landscape of tobacco product use in the United States."1

REFERENCES
1. FDA Proposes Significant Step Toward Reducing Nicotine to Minimally or Nonaddictive Level in Cigarettes and Certain Other Combusted Tobacco Products. News release. FDA. January 15, 2025. Accessed January 17, 2025. https://www.fda.gov/news-events/press-announcements/fda-proposes-significant-step-toward-reducing-nicotine-minimally-or-nonaddictive-level-cigarettes?utm_medium=email&utm_source=govdelivery
2. NIH. Tobacco, Nicotine, and E-Cigarettes Research Report How does tobacco deliver its effects? National Institute on Drug Abuse. January 2020. Accessed January 17, 2025. https://nida.nih.gov/publications/research-reports/tobacco-nicotine-e-cigarettes/how-does-tobacco-deliver-its-effects
3. CDC Lung Cancer Risk Factors. October 15, 2024. Accessed January 17, 2025. https://www.cdc.gov/lung-cancer/risk-factors/index.html#
Related Videos
Pharmacist and patient in a retail/community pharmacy setting -- Image credit: Zamrznuti tonovi | stock.adobe.com
Related Content
Advertisement
ASCO 2025: Pretreatment DPYD Testing for Fluoropyrimidines Can Improve Patient Safety and Lower Cost
May 29th 2025

ASCO 2025: Pretreatment DPYD Testing for Fluoropyrimidines Can Improve Patient Safety and Lower Cost

Alana Hippensteele, Lead Editor
Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings
May 28th 2025

Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings

Alexandra Gerlach, Associate Editor
FDA approval -- Image credit: Inovo Lab | stock.adobe.com
Published: May 29th 2025 | Updated: May 29th 2025

FDA Approves Khindivi, First Oral Solution of Hydrocortisone, for Pediatric Patients

Gillian McGovern, Associate Editor
pharmacy focus oncology podcast
May 19th 2025

Insights from a Pharmacy Times Peer Exchange: Real-World Outcomes and Supportive Care

Alexandra Gerlach, Associate Editor
Medical bottle with meningococcal disease vaccine and syringe, 3D rendering - Image credit: Alexey Novikov | stock.adobe.com
May 28th 2025

Quadrivalent Meningococcal Vaccine Receives FDA Approval for Infants and Children With Meningococcal Disease

Kennedy Ferruggia, Assistant Editor
ASCO 2025: Cost Savings and Clinical Outcomes of Pre-Treatment DPYD Genotyping Before Fluoropyrimidine Therapy
May 28th 2025

ASCO 2025: Cost Savings and Clinical Outcomes of Pre-Treatment DPYD Genotyping Before Fluoropyrimidine Therapy

Sarah Morris, PharmD Alana Hippensteele, Lead Editor
Related Content
Advertisement
ASCO 2025: Pretreatment DPYD Testing for Fluoropyrimidines Can Improve Patient Safety and Lower Cost
May 29th 2025

ASCO 2025: Pretreatment DPYD Testing for Fluoropyrimidines Can Improve Patient Safety and Lower Cost

Alana Hippensteele, Lead Editor
Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings
May 28th 2025

Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings

Alexandra Gerlach, Associate Editor
FDA approval -- Image credit: Inovo Lab | stock.adobe.com
Published: May 29th 2025 | Updated: May 29th 2025

FDA Approves Khindivi, First Oral Solution of Hydrocortisone, for Pediatric Patients

Gillian McGovern, Associate Editor
pharmacy focus oncology podcast
May 19th 2025

Insights from a Pharmacy Times Peer Exchange: Real-World Outcomes and Supportive Care

Alexandra Gerlach, Associate Editor
Medical bottle with meningococcal disease vaccine and syringe, 3D rendering - Image credit: Alexey Novikov | stock.adobe.com
May 28th 2025

Quadrivalent Meningococcal Vaccine Receives FDA Approval for Infants and Children With Meningococcal Disease

Kennedy Ferruggia, Assistant Editor
ASCO 2025: Cost Savings and Clinical Outcomes of Pre-Treatment DPYD Genotyping Before Fluoropyrimidine Therapy
May 28th 2025

ASCO 2025: Cost Savings and Clinical Outcomes of Pre-Treatment DPYD Genotyping Before Fluoropyrimidine Therapy

Sarah Morris, PharmD Alana Hippensteele, Lead Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Download on Apple
© 2025 MJH Life Sciences

All rights reserved.